Search Tag: #ESCcongress
2025 11 Sep
Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality and major adverse cardiovascular events compared with no therapy in patients with myocardial infarction (MI) and preserved or mildly reduced left ventricular ejection fraction (LVEF), according to results from the BETAMI and DANBLOCK trials. Findings are published...Read more
2025 01 Sep
Adding digital twin-guided ablation to standard pulmonary vein isolation (PVI) significantly improved outcomes in patients with persistent atrial fibrillation (AF), according to late-breaking results from the CUVIA-PRR trial presented at ESC Congress 2025. AF affects one in three adults worldwide and is characterised by fast, irregular heartbeats....Read more
2025 01 Sep
Pulsed field ablation (PFA) was not superior to radiofrequency ablation (RFA) in patients with drug-resistant paroxysmal atrial fibrillation (AF), according to results from the late-breaking BEAT-PAROX-AF trial presented in a Hot Line session at ESC Congress 2025. AF is the most common sustained cardiac arrhythmia. When antiarrhythmic drugs...Read more
2025 01 Sep
Discontinuing oral anticoagulation (OAC) therapy lowered the risk of a composite endpoint of stroke, systemic embolism, or major bleeding compared with continuing OAC in patients who had undergone successful atrial fibrillation (AF) ablation at least 12 months earlier, according to results from the late-breaking ALONE-AF (Anticoagulation One year after...Read more
2025 01 Sep
New ESC/EACTS Guidelines presented at ESC Congress 2025 aim to improve the diagnosis and treatment of patients with valvular heart disease, reflecting robust new evidence that supports broader and more consistent use of newer, less invasive treatment options. The guidelines were developed by an international panel of experts, co-chaired by...Read more
2025 01 Sep
In-hospital initiation of dapagliflozin did not significantly lower the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, according to late-breaking results from the DAPA ACT HF-TIMI 68 trial presented at ESC Congress 2025. However, a pooled analysis of trial data with other sodium-glucose cotransporter-2...Read more
2025 31 Aug
Digitoxin reduced the risk of a composite endpoint of all-cause death and hospitalisation for worsening heart failure (HF) in patients with advanced HF and reduced ejection fraction (HFrEF), according to late-breaking results from the DIGIT-HF trial presented in a Hot Line session at ESC Congress 2025. Cardiac glycosides such as digitoxin and...Read more
2025 31 Aug
Beta-blocker therapy did not reduce all-cause mortality, reinfarction, or heart failure (HF) admission in patients with myocardial infarction (MI) managed invasively who had left ventricular ejection fraction (LVEF) ≥40%, according to late-breaking results from the REBOOT trial presented in a Hot Line session at ESC Congress 2025 and published simultaneously...Read more
2025 30 Aug
A landmark ESC Clinical Consensus Statement presented at ESC Congress 2025 calls for greater recognition of the complex, two-way relationship between mental health and cardiovascular disease (CVD). It is the first statement of its kind developed by the European Society of Cardiology (ESC). The Statement urges systematic mental health screening...Read more
2025 30 Aug
A new ESC/EAS Focused Update on lipid management, released at ESC Congress 2025, provides fresh guidance on how best to reduce cardiovascular risk in patients. Central to the update is the recommendation to use new cardiovascular risk prediction algorithms, designed to help clinicians make more precise treatment decisions. The algorithms, SCORE2...Read more
2024 01 Sep
Adherence to atrial fibrillation (AF) guideline recommendations in clinical practice across Europe was found to be poor, but a structured educational programme for healthcare professionals significantly improved the implementation of heart rhythm control recommendations, according to research presented in a Hot Line session at the ESC Congress...Read more
2023 27 Aug
A recent trial involving all hospitals in London, U.K., reports no disparity in survival at 30 days in patients with resuscitated cardiac arrest who were transported by ambulance to a cardiac arrest centre or the nearest emergency department. These findings were presented during a Hot Line session at the ESC Congress 2023. Sudden cardiac arrest...Read more
2022 29 Aug
Late-breaking research presented at the ESC Congress shows that an artificial intelligence (AI) algorithm accurately estimates the risk of heart disease caused by cumulative exposure to cholesterol and blood pressure levels and the benefits of lowering both, thus providing the information needed to make individual treatment decisions. Atherosclerotic...Read more
2022 29 Aug
The latest research presented at the ESC Congress in Barcelona shows that conventional smartphone-assisted atrial fibrillation (AF) screening more than doubles the detection and treatment rate in older people compared to routine screening. AF is the most common heart rhythm disorder and affects over 40 million people worldwide. People with this...Read more
2022 27 Aug
Findings from the DANFLU-1 trial presented at the ESC Congress in Barcelona show that high-dose influenza vaccination in older adults reduces the risk of death by 49% and the incidence of hospitalisation for influenza or pneumonia by 64% compared with standard-dose vaccination. Several studies have previously investigated the association between...Read more
2022 27 Aug
The latest findings from the PERSPECTIVE trial were presented at the ESC Congress in Barcelona. The study aimed to evaluate sacubitril/valsartan compared with valsartan among symptomatic heart failure patients. The study included 592 patients with symptomatic heart failure. Two hundred and ninety-five patients received 97/103 mg sacubitril/valsartan,...Read more
2021 30 Aug
Late-breaking research from the PRONOUNCE trial was presented in a Hot Line session at ESC Congress 2021. The cardiovascular safety of androgen deprivation therapy (ADT) for prostate cancer remains unresolved after the trial was terminated early. Every year, approximately one million men are diagnosed with prostate cancer worldwide. These patients...Read more
2021 28 Aug
In another Hot Line session at the ESC Congress 2021, findings from the ENVISAGE-TAVI AF showed that edoxaban is non-inferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation. The prevalence of pre-existing or new-onset atrial fibrillation after TAVI ranges...Read more
2021 27 Aug
In a Hot Line Session at the ESC Congress 2021, the results of the EMPEROR-Preserved trial were presented that demonstrated a significant reduction in composite cardiovascular endpoints in patients with heart failure and preserved ejection fraction. This was a pooled analysis of two randomised trials that investigated the beneficial effects of...Read more
2021 27 Aug
At the ESC Congress 2021 today, latest insights into the progression to, and management of, heart failure were presented. Dr Carolyn Ho of Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA, discussed the results of the VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) trial. This trial...Read more
2021 26 Aug
The ESC Congress 2021, the world’s largest cardiovascular event, begins soon. Get ready for the hottest new science in cardiology from August 27-30. During the scientific meeting, all areas of cardiovascular disease will be covered across 15 channels. The spotlight this year will be on Sudden Cardiac Death. In addition, the congress will feature...Read more
2020 01 Sep
Heart patients hospitalised with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session today at ESC Congress 2020. ACE inhibitors and ARBs are commonly taken by heart patients to reduce blood pressure and to...Read more
2020 30 Aug
The main results of the DAPA-CK trial were presented today at ESC Congress 2020. Findings showed that dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. The goal of the DAPA-CKD trial was to...Read more
2020 30 Aug
New findings presented at the ESC Congress show that mavacemten improves heart function and symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). To date, the medical treatments for obstructive HCM focus on symptom relief but do not address the underlying causes. These treatments also offer modest efficacy with significant...Read more
2020 29 Aug
In a Hot Line session today at ESC Congress 2020, findings from the EMPEROR-Reduced trial showed that empagiflozin reduces the risk of cardiovascular death or hospitalisation for heart failure in patients with heart failure and a reduced ejection fraction. The findings are published in the New England Journal of Medicine. The clinical trial evaluated...Read more
2020 29 Aug
According to new findings presented at the ESC Congress 2020, influenza and pneumonia vaccinations are associated with fewer hospital deaths in heart failure patients. Approximately 26 million people are affected with heart failure worldwide. It is estimated that one out of five individuals will develop heart failure in their lifetime. Heart failure...Read more